BIG2-06 ALTTO

A randomised, multicentre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2+/ErbB2+ primary breast cancer.

Disease site: Breast cancer

Treatment Modality:

Status: Closed

Trial details

ALTTO is a Breast International Group (BIG) study with collaborative support provided by the ICR-CTSU. It is a randomised, open label multi-centre phase III study comparing the activity of lapatinib alone versus trastuzumab alone versus trastuzumab followed by lapatinib versus lapatinib concomitantly with trastuzumab in the adjuvant treatment of
patients with ErbB2 overexpressing and/or amplified breast cancer.

Chief Investigator: Professor Ian Smith (UK CI), Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

ISRCTN: N/A

Sponsor: GlaxoSmithKline

Funder: GlaxoSmithKline

Further information

Contact details and more information may be found on the ALTTO Trials homepage

ALTTO trials  listing on the UKCRN Portfolio

Tumour-infiltrating lymphocytes
Neoadjuvant radiotherapy provides unique insights into breast tumour immune microenvironment

30/01/25

A new study has provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumours.
See full story
3d reconstruction of the human breast
New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatment

06/02/25

Researchers have developed a new tool that could help clinicians diagnose the most common type of breast cancer more accurately and make better treatment decisions.
See full story